目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Viral Inactivation Variables, Trends, & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Viral Inactivation Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape

Chapter 4. Viral Inactivation Market: Product & Services Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Viral Inactivation Market: Product & services Movement Analysis, 2023 & 2030 (USD Million)
4.3. Kits & Reagents
4.3.1. Kits & Reagents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Systems & Accessories
4.4.1. Systems & Accessories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Services
4.5.1. Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Viral Inactivation Market: Application Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Viral Inactivation Market: Application Movement Analysis, 2023 & 2030 (USD Million)
5.3. Vaccines & Therapeutics
5.3.1. Vaccines & Therapeutics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Stem Cell Products
5.4.1. Stem Cell Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Blood & Blood Products
5.5.1. Blood & Blood Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Tissue/ Tissue Products
5.6.1. Tissue/ Tissue Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Cellular and Gene Therapy
5.7.1. Cellular and Gene Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Viral Inactivation Market: End Use Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Viral Inactivation Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
6.3. Pharmaceutical & Biotechnological Companies
6.3.1. Pharmaceutical & Biotechnological Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. CROs
6.4.1. CROs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Academic and Research Institutes
6.5.1. Academic and Research Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Others
6.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Viral Inactivation Market: Regional Estimates & Trend Analysis
7.1. Viral Inactivation Share, By Region, 2023 & 2030, USD Million
7.2. North America
7.2.1. North America Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. U.S. Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Canada Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.4. Mexico
7.2.4.1. Mexico Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. Europe Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.2. UK
7.3.2.1. UK Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Germany Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.4. France
7.3.4.1. France Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.5. Italy
7.3.5.1. Italy Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.6. Spain
7.3.6.1. Spain Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.7. Denmark
7.3.7.1. Denmark Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.8. Sweden
7.3.8.1. Sweden Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.9. Norway
7.3.9.1. Sweden Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.2. Japan
7.4.2.1. Japan Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.3. China
7.4.3.1. China Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.4. India
7.4.4.1. India Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.5. South Korea
7.4.5.1. South Korea Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.6. Thailand
7.4.6.1. Thailand Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Brazil Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.3. Argentina
7.5.3.1. Argentina Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Middle East and Africa
7.6.1. Middle East and Africa Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.2. South Africa
7.6.2.1. South Africa Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.3. Saudi Arabia
7.6.3.1. Saudi Arabia Viral Inactivation and Forecasts, 2018 - 2030 (USD Million)
7.6.4. UAE
7.6.4.1. UAE Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.5. Kuwait
7.6.5.1. Kuwait Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
8.4.1. Charles River Laboratories, Inc.
8.4.1.1. Participant’s Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Recent Developments/ Strategic Initiatives
8.4.2. Clean Cells
8.4.2.1. Participant’s Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Recent Developments/ Strategic Initiatives
8.4.3. Cytiva (Danaher Corporation)
8.4.3.1. Participant’s Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Recent Developments/ Strategic Initiatives
8.4.4. Merck KGaA
8.4.4.1. Participant’s Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Recent Developments/ Strategic Initiatives
8.4.5. Mettler Toledo
8.4.5.1. Participant’s Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Recent Developments/ Strategic Initiatives
8.4.6. Parker Hannifin Corp
8.4.6.1. Participant’s Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Recent Developments/ Strategic Initiatives
8.4.7. Rad Source Technologies Inc
8.4.7.1. Participant’s Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Recent Developments/ Strategic Initiatives
8.4.8. Sartorius AG
8.4.8.1. Participant’s Overview
8.4.8.2. Financial Performance
8.4.8.3. Product Benchmarking
8.4.8.4. Recent Developments/ Strategic Initiatives
8.4.9. Texcell SA
8.4.9.1. Participant’s Overview
8.4.9.2. Financial Performance
8.4.9.3. Product Benchmarking
8.4.9.4. Recent Developments/ Strategic Initiatives
8.4.10. Vironova AB
8.4.10.1. Participant’s Overview
8.4.10.2. Financial Performance
8.4.10.3. Product Benchmarking
8.4.10.4. Recent Developments/ Strategic Initiatives